



Pulmonary Arterial Hypertension (PAH) Drugs Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	133	PDF
Single User	Multi User	Enterprise	
USD 2,950	USD 4,430	USD 5,900	

Description

The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Drugs is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Berlin Cures, Daiichi Sankyo, Eiger BioPharmaceuticals, Glaxosmithkline and Northern Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pulmonary Arterial Hypertension (PAH) Drugs market in terms of revenue (US\$ million) and, where applicable, sales volume (W Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Pcs) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pulmonary Arterial Hypertension (PAH) Drugs Market by Company

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals
AstraZeneca
Berlin Cures
Daiichi Sankyo
Eiger BioPharmaceuticals
Glaxosmithkline
Northern Therapeutics
Reata Pharmaceuticals
United Therapeutics
Bayer Healthcare
Pfizer
Merck
Novartis

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type

Injectables
Inhalation
Oral Administration

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application

Hospitals
Clinics
Other

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Pulmonary Arterial Hypertension (PAH) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Pulmonary Arterial Hypertension (PAH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size (2021-2032)
 - 2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2032)
 - 2.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Average Price (2021-2032)
- 2.3 Pulmonary Arterial Hypertension (PAH) Drugs by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Injectables
 - 2.3.3 Inhalation
 - 2.3.4 Oral Administration
- 2.4 Pulmonary Arterial Hypertension (PAH) Drugs by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Hospitals
 - 2.4.3 Clinics
 - 2.4.4 Other

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs) of Manufacturers (2021-2026)
- 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Product Type & Application
- 3.8 Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Established Date
- 3.9 Global Pulmonary Arterial Hypertension (PAH) Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Actelion Pharmaceuticals
 - 4.1.1 Actelion Pharmaceuticals Company Information
 - 4.1.2 Actelion Pharmaceuticals Business Overview
 - 4.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
 - 4.1.5 Actelion Pharmaceuticals Recent Developments

4.2 Aires Pharmaceuticals

4.2.1 Aires Pharmaceuticals Company Information

4.2.2 Aires Pharmaceuticals Business Overview

4.2.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.2.5 Aires Pharmaceuticals Recent Developments

4.3 Arena Pharmaceuticals

4.3.1 Arena Pharmaceuticals Company Information

4.3.2 Arena Pharmaceuticals Business Overview

4.3.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.3.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.3.5 Arena Pharmaceuticals Recent Developments

4.4 AstraZeneca

4.4.1 AstraZeneca Company Information

4.4.2 AstraZeneca Business Overview

4.4.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.4.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.4.5 AstraZeneca Recent Developments

4.5 Berlin Cures

4.5.1 Berlin Cures Company Information

4.5.2 Berlin Cures Business Overview

4.5.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.5.5 Berlin Cures Recent Developments

4.6 Daiichi Sankyo

4.6.1 Daiichi Sankyo Company Information

4.6.2 Daiichi Sankyo Business Overview

4.6.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.6.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.6.5 Daiichi Sankyo Recent Developments

4.7 Eiger BioPharmaceuticals

4.7.1 Eiger BioPharmaceuticals Company Information

4.7.2 Eiger BioPharmaceuticals Business Overview

4.7.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.7.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.7.5 Eiger BioPharmaceuticals Recent Developments

4.8 Glaxosmithkline

4.8.1 Glaxosmithkline Company Information

4.8.2 Glaxosmithkline Business Overview

4.8.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.8.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.8.5 Glaxosmithkline Recent Developments

4.9 Northern Therapeutics

4.9.1 Northern Therapeutics Company Information

4.9.2 Northern Therapeutics Business Overview

4.9.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.9.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.9.5 Northern Therapeutics Recent Developments

4.10 Reata Pharmaceuticals

4.10.1 Reata Pharmaceuticals Company Information

4.10.2 Reata Pharmaceuticals Business Overview

4.10.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.10.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.10.5 Reata Pharmaceuticals Recent Developments

4.11 United Therapeutics

4.11.1 United Therapeutics Company Information

4.11.2 United Therapeutics Business Overview

4.11.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.11.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.11.5 United Therapeutics Recent Developments

4.12 Bayer Healthcare

4.12.1 Bayer Healthcare Company Information

4.12.2 Bayer Healthcare Business Overview

4.12.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.12.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.12.5 Bayer Healthcare Recent Developments

4.13 Pfizer

4.13.1 Pfizer Company Information

4.13.2 Pfizer Business Overview

4.13.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.13.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.13.5 Pfizer Recent Developments

4.14 Merck

4.14.1 Merck Company Information

4.14.2 Merck Business Overview

4.14.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.14.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.14.5 Merck Recent Developments

4.15 Novartis

4.15.1 Novartis Company Information

4.15.2 Novartis Business Overview

4.15.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)

4.15.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

4.15.5 Novartis Recent Developments

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Scenario by Region

5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021-2032

5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021-2026

5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2027-2032

5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2021-2032

5.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2021-2026

5.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2027-2032

5.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country

- 5.4.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
 - 5.4.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
 - 5.5 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
 - 5.5.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
 - 5.5.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
 - 5.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
 - 5.7 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
 - 5.7.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
 - 5.7.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
 - 5.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2032)
 - 5.8.4 Egypt
 - 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)

6.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032) & (W Pcs)

6.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2032)

6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)

6.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2032)

6.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)

7 Segment by Application

7.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)

7.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032) & (W Pcs)

7.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2032)

7.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)

7.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2032)

7.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Analysis

8.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process

8.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors

8.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers

9 Global Pulmonary Arterial Hypertension (PAH) Drugs Analyzing Market Dynamics

9.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends

9.2 Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers

9.3 Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges

9.4 Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Pulmonary Arterial Hypertension (PAH) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs) of Manufacturers (2021-2026)
- Table 7: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue of Manufacturers (2021-2026)
- Table 9: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (US\$/Pcs) of Manufacturers (2021-2026)
- Table 11: Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Product Type & Application
- Table 14: Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Pulmonary Arterial Hypertension (PAH) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Actelion Pharmaceuticals Company Information
- Table 19: Actelion Pharmaceuticals Business Overview
- Table 20: Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 21: Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 22: Actelion Pharmaceuticals Recent Developments
- Table 23: Aires Pharmaceuticals Company Information
- Table 24: Aires Pharmaceuticals Business Overview
- Table 25: Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 26: Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 27: Aires Pharmaceuticals Recent Developments
- Table 28: Arena Pharmaceuticals Company Information
- Table 29: Arena Pharmaceuticals Business Overview
- Table 30: Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 31: Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 32: Arena Pharmaceuticals Recent Developments
- Table 33: AstraZeneca Company Information
- Table 34: AstraZeneca Business Overview
- Table 35: AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 36: AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 37: AstraZeneca Recent Developments
- Table 38: Berlin Cures Company Information
- Table 39: Berlin Cures Business Overview
- Table 40: Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 41: Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 42: Berlin Cures Recent Developments
- Table 43: Daiichi Sankyo Company Information
- Table 44: Daiichi Sankyo Business Overview
- Table 45: Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 46: Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio

- Table 47: Daiichi Sankyo Recent Developments
- Table 48: Eiger BioPharmaceuticals Company Information
- Table 49: Eiger BioPharmaceuticals Business Overview
- Table 50: Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 51: Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 52: Eiger BioPharmaceuticals Recent Developments
- Table 53: Glaxosmithkline Company Information
- Table 54: Glaxosmithkline Business Overview
- Table 55: Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 56: Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 57: Glaxosmithkline Recent Developments
- Table 58: Northern Therapeutics Company Information
- Table 59: Northern Therapeutics Business Overview
- Table 60: Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 61: Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 62: Northern Therapeutics Recent Developments
- Table 63: Reata Pharmaceuticals Company Information
- Table 64: Reata Pharmaceuticals Business Overview
- Table 65: Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 66: Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 67: Reata Pharmaceuticals Recent Developments
- Table 68: United Therapeutics Company Information
- Table 69: United Therapeutics Business Overview
- Table 70: United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 71: United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 72: United Therapeutics Recent Developments
- Table 73: Bayer Healthcare Company Information
- Table 74: Bayer Healthcare Business Overview
- Table 75: Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 76: Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 77: Bayer Healthcare Recent Developments
- Table 78: Pfizer Company Information
- Table 79: Pfizer Business Overview
- Table 80: Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 81: Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 82: Pfizer Recent Developments
- Table 83: Merck Company Information
- Table 84: Merck Business Overview
- Table 85: Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 86: Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 87: Merck Recent Developments
- Table 88: Novartis Company Information
- Table 89: Novartis Business Overview
- Table 90: Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 91: Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
- Table 92: Novartis Recent Developments
- Table 93: Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 94: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026) & (W Pcs)
- Table 95: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2021-2026)
- Table 96: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032) & (W Pcs)
- Table 97: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2027-2032)
- Table 98: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2021-2026) & (US\$ Million)
- Table 99: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2021-2026)
- Table 100: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2027-2032) & (US\$ Million)
- Table 101: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2027-2032)
- Table 102: North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$

Million)

- Table 103: North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs)
- Table 104: North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs)
- Table 105: North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 106: North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 107: Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs)
- Table 109: Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs)
- Table 110: Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs)
- Table 114: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs)
- Table 115: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs)
- Table 119: South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs)
- Table 120: South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs)
- Table 124: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs)
- Table 125: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs)
- Table 128: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs)
- Table 129: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2026)
- Table 130: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2027-2032)
- Table 131: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US\$ Million)
- Table 132: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US\$ Million)
- Table 133: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2026)
- Table 134: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2027-2032)
- Table 135: Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2026) & (US\$/Pcs)
- Table 136: Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2027-2032) & (US\$/Pcs)
- Table 137: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs)
- Table 138: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs)
- Table 139: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2026)
- Table 140: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2027-2032)
- Table 141: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US\$ Million)
- Table 142: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US\$ Million)
- Table 143: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2026)
- Table 144: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2027-2032)
- Table 145: Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2026) & (US\$/Pcs)
- Table 146: Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2027-2032) & (US\$/Pcs)
- Table 147: Key Raw Materials
- Table 148: Raw Materials Key Suppliers
- Table 149: Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
- Table 150: Pulmonary Arterial Hypertension (PAH) Drugs Customers List
- Table 151: Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
- Table 152: Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers
- Table 153: Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints
- Table 154: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed

- Figure 4: Pulmonary Arterial Hypertension (PAH) Drugs Product Image
- Figure 5: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2032) & (W Pcs)
- Figure 8: Global Pulmonary Arterial Hypertension (PAH) Drugs Average Price (US\$/Pcs) & (2021-2032)
- Figure 9: Injectables Product Image
- Figure 10: Inhalation Product Image
- Figure 11: Oral Administration Product Image
- Figure 12: Hospitals Product Image
- Figure 13: Clinics Product Image
- Figure 14: Other Product Image
- Figure 15: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers in 2025
- Figure 16: Global Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, Manufacturing Sites & Headquarters
- Figure 17: Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Drugs Players Market Share by Revenue in 2025
- Figure 18: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 19: Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 20: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region in 2025
- Figure 21: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region in 2025
- Figure 22: North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country in 2025
- Figure 23: North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2032)
- Figure 24: North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2021-2032)
- Figure 25: United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country in 2025
- Figure 29: Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2032)
- Figure 30: Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2021-2032)
- Figure 31: Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: France Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Spain Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Switzerland Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Sweden Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Poland Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country in 2025
- Figure 42: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2032)
- Figure 43: Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2021-2032)
- Figure 44: China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: India Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Australia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country in 2025
- Figure 53: South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2032)
- Figure 54: South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2021-2032)
- Figure 55: Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Chile Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country in 2025
- Figure 59: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2032)
- Figure 60: Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2021-2032)
- Figure 61: Egypt Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: South Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: Israel Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Türkiye Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: GCC Countries Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2032)
- Figure 67: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2032)

- Figure 68: Global Pulmonary Arterial Hypertension (PAH) Drugs Price (US\$/Pcs) by Type (2021-2032)
- Figure 69: Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2032)
- Figure 70: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2032)
- Figure 71: Global Pulmonary Arterial Hypertension (PAH) Drugs Price (US\$/Pcs) by Application (2021-2032)
- Figure 72: Pulmonary Arterial Hypertension (PAH) Drugs Value Chain
- Figure 73: Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process
- Figure 74: Direct Comparison with Distribution Share
- Figure 75: Distributors Profiles
- Figure 76: Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges